Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.60 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.58 |
| ▸ | POLB | P06746 | 1/20 | 0.57 |
| ▸ | LMNA | P02545 | 1/20 | 0.55 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.55 |
| ▸ | CD274 | Q9NZQ7 | 2/20 | 0.54 |
| ▸ | HTR1A | P08908 | 1/20 | 0.54 |
| ▸ | MAOA | P21397 | 1/20 | 0.54 |
| ▸ | MAOB | P27338 | 1/20 | 0.54 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.54 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12844562 | 0.85 | SMN1; SMN2 (0.58) | SMN1; SMN2ALDH1A1POLBLMNAKMT2A | |
| SCHEMBL12775340 | 0.84 | SMN1; SMN2 (0.57) | SMN1; SMN2ALDH1A1POLBLMNAKMT2A | |
| SCHEMBL12141908 | 0.84 | ALDH1A1 (0.57) | SMN1; SMN2ALDH1A1POLBLMNAKMT2A | |
| SCHEMBL12302077 | 0.79 | POLB (0.66) | ALDH1A1POLBCD274HTR1AMAOA | |
| SCHEMBL17788474 | 0.78 | ALDH1A1 (0.69) | SMN1; SMN2ALDH1A1POLBLMNAKMT2A | |
| SCHEMBL12012694 | 0.78 | SMN1; SMN2 (0.58) | SMN1; SMN2ALDH1A1POLBLMNAKMT2A | |
| SCHEMBL13852608 | 0.78 | ALDH1A1 (0.62) | SMN1; SMN2ALDH1A1POLBLMNAKMT2A | |
| SCHEMBL14190871 | 0.78 | RAB9A (0.62) | ALDH1A1LMNAKMT2A | |
| SCHEMBL28670109 | 0.77 | MAOB (0.68) | SMN1; SMN2ALDH1A1CD274HTR1AMAOA | |
| SCHEMBL15526795 | 0.76 | SMN1; SMN2 (0.53) | SMN1; SMN2ALDH1A1POLBLMNAKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7902373-B2 | asthma; for treating prostaglandin D2 mediated diseases; e.g. 6-(3-fluorophenyl)-N-[1-(1-methyl-1H-tetrazol-5-yl)piperidin-4-yl]nicotinamide | PFIZER INC (US) | 2011-03-08 | — | — | US | disclosed |
| WO-2008104869-A1 | NICOTINAMIDE DERIVATIVES AS INHIBITORS OF H-PGDS AND THEIR USE FOR TREATING PROSTAGLANDIN D2 MEDIATED DISEASES | PFIZER PRODUCTS INC. (US) | 2008-09-04 | — | — | WO | disclosed |
| WO-2008075172-A2 | NICOTINAMIDE DERIVATIVES AS INHIBITORS OF H-PGDS AND THEIR USE FOR TREATING PROSTAGLANDIN D2 MEDIATED DISEASES | PFIZER PRODUCTS INC. (US) | 2008-06-26 | — | — | WO | disclosed |
| US-20080146569-A1 | Nicotinamide Derivatives | PFIZER INC. | 2008-06-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080146569-A1 | Nicotinamide Derivatives | NNT, NAMPT, NADK | SMN1; SMN2 1371/4885ALDH1A1 148/4885POLB 2232/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.